New York, United States
ProJenX, founded in 2021, is a clinical-stage biotechnology company based in the United States. Specializing in targeted, brain-penetrant treatments for neurodegenerative diseases, it focuses initially on ALS with its lead therapy candidate, prosetin.
Emerging from a collaboration with Project ALS and Columbia University, ProJenX stands out for its innovative, patient-specific, cell-based discovery platform. This proprietary technology can potentially pave the way for additional transformative medicines in the neuroscience field.
This company operates within the Biopharma, Biotechnology, Health Care, and Health and Wellness industries, encapsulating a broad market opportunity.
ProJenX received its latest investment, a $1.00M grant, on June 20, 2024, from The ALS Association, highlighting both confidence in its inventive therapies and a stable funding avenue critical for clinical development stages.
